metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) 5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population 5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant 1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative 1
mNSCLC - L2 - PDL1 positive 7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population 1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population 1
squamous - mNSCLC - L2 - PDL1 positive

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (2mg/kg)

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs docetaxel
vs Standard of Care (SoC)

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open